Quickstart Highlights
Tirzepatide is a 39–amino acid dual incretin receptor agonist that activates both GLP‑1 and GIP receptors, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Its ~5‑day half‑life allows convenient once‑weekly subcutaneous dosing. Clinical trials demonstrate superior glycemic control and weight reduction compared to selective GLP‑1 agonists.
- Reconstitute: Add 2.0 mL bacteriostatic water → 25.0 mg/mL concentration.
- Typical weekly range: 2.5–15 mg once weekly on the same day each week (4-week minimum per titration step); continuous use with no off-cycle until the desired weight is achieved, then hold a maintenance dose of 5, 10 or 15 mg.
- Easy measuring: At 25.0 mg/mL, 1 unit = 0.01 mL = 250 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days.
Dosing & Reconstitution Guide
Standard / Gradual Approach (2 mL = 25.0 mg/mL)
| Phase | Weekly Dose (mg) | Units (per injection) (mL) | V1 nominal setting (units) |
|---|---|---|---|
| Weeks 1–4 | 2.5 mg | 10 units (0.10 mL) × 1 injection | 10 units |
| Weeks 5–8 | 5 mg | 20 units (0.20 mL) × 1 injection | 20 units |
| Weeks 9–12 | 7.5 mg | 30 units (0.30 mL) × 1 injection | 30 units |
| Weeks 13–16 | 10 mg | 40 units (0.40 mL) × 1 injection | 40 units |
Frequency: Inject once weekly subcutaneously on the same day each week. For doses requiring multiple injections, administer consecutively at different sites. Dose increases occur every 4 weeks to minimize gastrointestinal side effects. Higher doses (12.5–15 mg/week) may be used in subsequent phases if tolerated and clinically indicated. Continuous, once weekly on the same day; no off-cycle. Continue until the desired weight is achieved, then hold the maintenance dose (5, 10 or 15 mg) or taper under clinical guidance.
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- Use within 28 days of reconstitution.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on the first 16 weeks of continuous use with gradual titration (once-weekly dosing); there is no off-cycle, so budget the maintenance line below for each further 4 weeks.
- Peptide Vials (Tirzepatide, 50 mg each):
- 8 weeks (2.5→5 mg/wk): ~30 mg total ≈ 1 vial
- 12 weeks (2.5→7.5 mg/wk): ~60 mg total ≈ 2 vials
- 16 weeks (2.5→10 mg/wk): ~100 mg total ≈ 2 vials
- Maintenance, per 4 weeks: 10 mg/wk = 40 mg ≈ 1 vial; 15 mg/wk = 60 mg ≈ 2 vials (1.2 vials used)
- Insulin Syringes (U‑100, 1 mL):
- 8 weeks: 8 syringes (1/week)
- 12 weeks: 12 syringes (1/week)
- 16 weeks: 16 syringes (1/week)
- Bacteriostatic Water (30 mL bottles): Use 2.0 mL per vial for reconstitution.
- 8 weeks (1 vial): 2 mL → 1 × 30 mL bottle
- 12 weeks (2 vials): 4 mL → 1 × 30 mL bottle
- 16 weeks (2 vials): 4 mL → 1 × 30 mL bottle
- Alcohol Swabs: One for the vial stopper + one for the injection site each administration day.
- Per week: 2 swabs (1 injection day)
- 8 weeks: 16 swabs → recommend 1 × 100‑count box
- 12 weeks: 24 swabs → recommend 1 × 100‑count box
- 16 weeks: 32 swabs → recommend 1 × 100‑count box
Protocol Overview
Concise summary of the once‑weekly regimen.
- Goal: Support glycemic control, weight management, and metabolic health through dual incretin receptor activation.
- Schedule: Weekly subcutaneous injection on the same day each week, stepping up every 4 weeks or longer; continuous use with no off-cycle until the desired weight is achieved.
- Dose Range: 2.5–15 mg weekly with 4‑week titration intervals.
- Cycle Length / Maintenance: Continuous, once weekly on the same day; no off-cycle. Continue until the desired weight is achieved, then hold the maintenance dose (5, 10 or 15 mg) or taper under clinical guidance.
- Reconstitution: 2.0 mL per 50 mg vial (25.0 mg/mL) for manageable injection volumes.
- Storage: Lyophilized frozen; reconstituted refrigerated for up to 28 days.
Dosing Protocol
Suggested weekly titration approach.
- Start: 2.5 mg once weekly for 4 weeks (initiation dose).
- Escalate: Increase by 2.5 mg every 4 weeks or longer as tolerated.
- Maintenance: 5, 10 or 15 mg weekly based on response and tolerability; hold the maintenance dose once the desired weight is achieved, or taper under clinical guidance.
- Frequency: Once per week (subcutaneous), same day each week.
- Cycle Length: Continuous, once weekly on the same day; no off-cycle. Continue until the desired weight is achieved, then hold the maintenance dose (5, 10 or 15 mg) or taper under clinical guidance.
- Timing: Any time of day; with or without food; rotate injection sites.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution.
- Shelf life: Use reconstituted solution within 28 days.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- All doses in this protocol — including the top 10 mg/week phase — fit in a single 1 mL syringe at this 25.0 mg/mL concentration; the 50 mg vial’s higher concentration means no dose ever needs to be split across two injections, unlike the 10 mg vial.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document weekly dose, date, and injection site to maintain consistency.
- Gastrointestinal effects (nausea, diarrhea) are common initially; gradual titration helps minimize them.
How This Works
Tirzepatide is a novel dual agonist that simultaneously activates GLP‑1 (glucagon‑like peptide‑1) and GIP (glucose‑dependent insulinotropic polypeptide) receptors. This dual mechanism enhances glucose‑dependent insulin secretion while suppressing glucagon release, slowing gastric emptying, and promoting satiety through central appetite regulation. The added GIP activity appears to synergistically amplify metabolic effects beyond GLP‑1 alone, contributing to superior weight reduction observed in clinical trials. Its ~5‑day half‑life enables convenient once‑weekly administration.
Potential Benefits & Side Effects
Observations from clinical trials and published literature.
- Glycemic control: Significant HbA1c reductions in type 2 diabetes trials.
- Weight reduction: Clinical trials report substantial body‑weight loss (up to ~11 kg more than GLP‑1 RA comparators over 26 weeks at higher doses).
- Cardiovascular markers: Improvements in lipid profiles and blood pressure observed in some studies.
- Common side effects: Gastrointestinal (nausea, diarrhea, vomiting, constipation) — typically mild‑to‑moderate and dose‑dependent; gradual titration reduces incidence.
- Injection‑site reactions: Occasional mild redness or irritation at subcutaneous injection sites.
Lifestyle Factors
Complementary strategies for best outcomes.
- Pair with a balanced, calorie‑appropriate diet; reduced appetite may naturally decrease intake.
- Prioritize protein to preserve lean mass during weight loss.
- Combine resistance training and aerobic activity to support metabolic health.
- Stay hydrated, especially given potential gastrointestinal effects.
- Prioritize sleep and stress management to support adherence and recovery.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources.
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen avoiding 2‑inch radius around navel, outer thighs, upper arms) to avoid lipohypertrophy.
- Dispose of needles and syringes in a sharps container immediately after use.
Recommended Source
Why Amino Labs?
- Third-party tested: Each batch includes Certificate of Analysis (COA) verifying purity and composition.
- Consistent quality: ISO-aligned manufacturing and handling standards ensure reliable product integrity.
- Cold-chain integrity: Temperature-controlled shipping and storage throughout fulfillment process.
- Research-grade purity: Suitable for educational and research applications requiring high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.